Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

Bioorg Med Chem. 2016 Dec 15;24(24):6390-6400. doi: 10.1016/j.bmc.2016.11.008. Epub 2016 Nov 9.

Abstract

Animal infection models in the pharmacokinetic/pharmacodynamic (PK/PD) evaluation of antimicrobial therapy serve an important role in preclinical assessments of new antibiotics, dosing optimization for those that are clinically approved, and setting or confirming susceptibility breakpoints. The goal of animal model studies is to mimic the infectious diseases seen in humans to allow for robust PK/PD studies to find the optimal drug exposures that lead to therapeutic success. The PK/PD index and target drug exposures obtained in validated animal infection models are critical components in optimizing dosing regimen design in order to maximize efficacy while minimize the cost and duration of clinical trials. This review outlines the key components in animal infection models which have been used extensively in antibiotic discovery and development including PK/PD analyses.

Keywords: Animal model; Drug development; Pharmacodynamics; Pharmacokinetics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects*
  • Bacterial Infections / drug therapy*
  • Disease Models, Animal*
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents